MedTrace Logo

Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients

NCT04875299 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2021-08-25

No results posted yet for this study

Summary

The optimal plasma concentration range of adalimumab in Chinese patients with active ankylosing spondylitis remains unknown, the aims of this study is to determine the concentration-effect relationship, and explore the effect of anti-drug antibody or biomarkers on clinical outcomes in a real-world setting.

Conditions

Interventions

OTHER

The study is observational

The study is observational

Sponsors & Collaborators

  • Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator OTHER

  • Central South University

    collaborator OTHER

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Tianjin First Central Hospital

    collaborator OTHER

  • Wuxi No. 2 People's Hospital

    collaborator OTHER

  • The First People's Hospital of Changzhou

    collaborator OTHER

  • Affiliated Hospital of Nantong University

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Qingdao Municipal Hospital

    collaborator OTHER

  • Liaocheng People's Hospital

    collaborator OTHER

  • Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Liyan Miao, Ph.D · The Affiliated Hospital of Soochow University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-01-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04875299 on ClinicalTrials.gov